SlideShare a Scribd company logo
1 of 1
DNA binding, DNA Methylation and Cell Toxicity of Estradiol Conjugated DNA
Methylating Compounds
Estrogen Receptor Binding :FRET Assay
Cell Toxicity
DNA Methylation
Design of Molecules
Acknowledgments
Matthew Powella, Sean Millera, Rigel Kishtona, Charles Kellya, Kelly Mastroa, Astrid Linaresb, Manoj Chelvanambib, Vinayak K. Gorec, Giridhar R.
Akkarajub Sridhar Varadarajana,*aDepartment of Chemistry and Biochemistry, University of North Carolina Wilmington, Wilmington, NC, bDepartment of
Biology, Texas Christian University, Fort Worth, TX, cQuality Chemical Laboratories, Wilmington, NC.
Abstract
Estradiol conjugated compounds that can target estrogen receptor positive cells and
produce lethal N3-methyladenine adducts in these cells have been synthesized and
investigated1. Prior studies with these DNA methylating compounds had shown that the
ability of these molecules to produce N3-methyladenine adducts was crucially dependent
on the composition of the linker unit connecting the DNA methylating moiety to the
estradiol unit. The DNA binding properties of this class of molecules was investigated
using stable non-methylating analogs, and the variation in the DNA binding ability of the
compounds was compared to the corresponding DNA methylating ability. Cell toxicity
studies were conducted using MCF-7 breast cancer cells in order to determine any
correlation between toxicity and DNA methylation and estrogen receptor binding. The
results of these studies are presented.
References
0
20
40
60
80
100
120
140
0 20 40 60 80 100 120
%Control(CellSurvival)
Concentration (uM)
Cell Survival
Melex
1a
2a
3a
Linear (Melex)
Linear (1a)
Linear (2a)
Linear (3a)
0
20
40
60
80
100
120
140
0 20 40 60 80 100 120
%Control(CellSurvival)
Concentration (uM)
Cell Survival - Control
Control
1b
2b
3b
Linear (Control)
Linear (1b)
Linear (2b)
Linear (3b)
Compound IC50 (nM) Relative Binding Affinity
Estradiol 0.58 100%
1b 0.99 58%
2b 1.48 39%
3b 1.11 52%
Synthesis of Molecules3
• Toxicity of compounds was determined in
MCF-7 breast cancer cells that
overexpress estrogen receptor-α.
• All methyl-sulfonates were toxic to MCF-
7 cells, with compound 2a being the most
toxic (EC50 ≈ 40 μM ), followed by 3a,
and then 1a.
• All sulfone analogues were not toxic to
MCF-7 cells.
• 3Me-A is the predominant adduct formed by all
three compounds
• Compound 2a produces significantly higher
levels of 3-MeA relative to the other
compounds.
Possible explanation for the variation in
DNA binding of compounds.
1. Franza, Gilberto, and Barry Gold. "The Biological Effects of N3-
methyladenine." Journal of Cellular Biochemistry 19.2 (2004): 250-257. Web. Aug. &
Sept. 2013.
2. Charles Kelly
3. Kishton, Rigel, Sean E. Miller, Heather Perry, Tera Lynch, Mayur Patel, Vinayak K. Gore,
and Giridhar R. Akkaraju. "DNA Site-specific N3-adenine Methylation Targeted to
Estrogen Receptor-positive Cells." Biorganic and Medicinal Chemistry 195093-5102.
This project was funded in part by: the NC Biotechnology Center Research Grant (#CC6425),
the Research Corporation (#2008BRG1214), the GlaxoSmithKline Summer Undergraduate
Research Scholarship, and the UNCW CSURF Research Supplies award, UNCW CSURF
Undergraduate Fellowships, and the UNCW Charles L. Cahill Award. We also thank Dr.
Suzanne Wardell and Dr. Donald McDeonnell for help with gene transcription studies.
Compound 2
Compound 1
Table 1
DNA adduct levels obtained upon reaction of compounds
with calf thymus DNAa
Comp-
ound
conc
µM
netrop
µM
adduct level
µmol adduct/mol DNA
3-MeA 7-MeG
1 25 1615 ± 45 194 ± 35
50 1764 ± 17 280 ± 36
100 1922 ± 35 404 ± 109
100 100 180 ± 10 482 ± 57
2 25 6523 ± 363 93 ± 31
50 11131 ± 30 253 ± 10
100 14449 ± 161 495 ± 35
100 100 769 ± 42 409 ± 3
3 25 699 ± 19 147 ± 20
50 922 ± 31 204 ± 25
100 1206 ± 23 318 ± 15
100 100 173 ± 16 420 ± 73
Me-lex 25 4599 ± 385 185 ± 59
50 8234 ± 542 399 ± 108
100 14280 ± 1250 774 ± 73
100 100 657 ± 12 714 ± 67
MMS 5000 1799 ± 39 18067 ± 76
5000 100 1239 ± 88 18935 ± 502
a DNA (1 mM) was reacted with methylating compounds, in the
presence or absence of netropsin, for 24 h at RT in 10 mM sodium
cacodylate buffer (pH 7.0) containing 10% DMSO.
0
2000
4000
6000
8000
10000
12000
14000
16000
1 2 3 Me-lex MMS
Adduct levels (μmol adduct/mol DNA)
3-MeA
7-MeG
DNA Binding:
Fluorescent Intercalator Displacement Assay
Estrogen Receptor Gene Transcription
A. Duplex DNA
B. Ethidium bromide intercalated DNA
exhibits fluorescence enhancement.
C. EtBris displaced by ligand and
fluorescence diminishes.
800000
1000000
1200000
1400000
1600000
1800000
2000000
1 2 3 4 5 6 7
FluorescenceIntensity
molar eq. compound
DNA Binding Assay
4.72 eq.
4.43 eq.
2.54 eq.
1b
2b
3b
• Compounds act as SERMS.
• Stereoview of compound 3a bound in the
minor groove of DNA2

More Related Content

What's hot

Comparative evaluation of physical and chemical mutagens
Comparative evaluation of physical and chemical mutagensComparative evaluation of physical and chemical mutagens
Comparative evaluation of physical and chemical mutagensANANDALEKSHMIL
 
Austin Journal of Reproductive Medicine & Infertility
Austin Journal of Reproductive Medicine & InfertilityAustin Journal of Reproductive Medicine & Infertility
Austin Journal of Reproductive Medicine & InfertilityAustin Publishing Group
 
Virtual screening studies in search of dopamine D1 receptor ligands as antips...
Virtual screening studies in search of dopamine D1 receptor ligands as antips...Virtual screening studies in search of dopamine D1 receptor ligands as antips...
Virtual screening studies in search of dopamine D1 receptor ligands as antips...Monika Marcinkowska
 
Cancer epigenetics
Cancer epigeneticsCancer epigenetics
Cancer epigeneticsArad Boustan
 
Trade-Offs and Kinetic Control for Kinetic Proofreading Networks in Biologica...
Trade-Offs and Kinetic Control for Kinetic Proofreading Networks in Biologica...Trade-Offs and Kinetic Control for Kinetic Proofreading Networks in Biologica...
Trade-Offs and Kinetic Control for Kinetic Proofreading Networks in Biologica...JoelMallory2
 
An introduction to population based data for studies of DNA methylation
An introduction to population based data for studies of DNA methylationAn introduction to population based data for studies of DNA methylation
An introduction to population based data for studies of DNA methylationDavid Rehkopf
 
acs.jmedchem.5b01760
acs.jmedchem.5b01760acs.jmedchem.5b01760
acs.jmedchem.5b01760Marta Wylot
 
Brianna Betton poster 071816- Final
Brianna Betton poster 071816- FinalBrianna Betton poster 071816- Final
Brianna Betton poster 071816- FinalBrianna Betton
 
CVA Biology I - B10vrv4133
CVA Biology I - B10vrv4133CVA Biology I - B10vrv4133
CVA Biology I - B10vrv4133ClayVirtual
 
P53_Final_Presentation
P53_Final_PresentationP53_Final_Presentation
P53_Final_PresentationJonah Kohen
 
PAG Jan 2011: Epigenetic Regulation in the Pacific Oyster
PAG Jan 2011: Epigenetic Regulation in the Pacific OysterPAG Jan 2011: Epigenetic Regulation in the Pacific Oyster
PAG Jan 2011: Epigenetic Regulation in the Pacific Oystermgavery
 
ResearchPoster_USFHealthFair
ResearchPoster_USFHealthFairResearchPoster_USFHealthFair
ResearchPoster_USFHealthFairKonstantin Ravvin
 
Medicinal application of organometallic compounds
Medicinal application of organometallic compoundsMedicinal application of organometallic compounds
Medicinal application of organometallic compoundsALIRAZA2498
 

What's hot (20)

Comparative evaluation of physical and chemical mutagens
Comparative evaluation of physical and chemical mutagensComparative evaluation of physical and chemical mutagens
Comparative evaluation of physical and chemical mutagens
 
Dharmendra
DharmendraDharmendra
Dharmendra
 
Austin Journal of Reproductive Medicine & Infertility
Austin Journal of Reproductive Medicine & InfertilityAustin Journal of Reproductive Medicine & Infertility
Austin Journal of Reproductive Medicine & Infertility
 
Epigenetics
EpigeneticsEpigenetics
Epigenetics
 
Virtual screening studies in search of dopamine D1 receptor ligands as antips...
Virtual screening studies in search of dopamine D1 receptor ligands as antips...Virtual screening studies in search of dopamine D1 receptor ligands as antips...
Virtual screening studies in search of dopamine D1 receptor ligands as antips...
 
Cancer epigenetics
Cancer epigeneticsCancer epigenetics
Cancer epigenetics
 
LSD1 - bmc-paper
LSD1 - bmc-paperLSD1 - bmc-paper
LSD1 - bmc-paper
 
Trade-Offs and Kinetic Control for Kinetic Proofreading Networks in Biologica...
Trade-Offs and Kinetic Control for Kinetic Proofreading Networks in Biologica...Trade-Offs and Kinetic Control for Kinetic Proofreading Networks in Biologica...
Trade-Offs and Kinetic Control for Kinetic Proofreading Networks in Biologica...
 
An introduction to population based data for studies of DNA methylation
An introduction to population based data for studies of DNA methylationAn introduction to population based data for studies of DNA methylation
An introduction to population based data for studies of DNA methylation
 
acs.jmedchem.5b01760
acs.jmedchem.5b01760acs.jmedchem.5b01760
acs.jmedchem.5b01760
 
Brianna Betton poster 071816- Final
Brianna Betton poster 071816- FinalBrianna Betton poster 071816- Final
Brianna Betton poster 071816- Final
 
Epigenetics final
Epigenetics finalEpigenetics final
Epigenetics final
 
CARO meeting 2012
CARO meeting 2012CARO meeting 2012
CARO meeting 2012
 
CVA Biology I - B10vrv4133
CVA Biology I - B10vrv4133CVA Biology I - B10vrv4133
CVA Biology I - B10vrv4133
 
P53_Final_Presentation
P53_Final_PresentationP53_Final_Presentation
P53_Final_Presentation
 
članek_Buzar
članek_Buzarčlanek_Buzar
članek_Buzar
 
PAG Jan 2011: Epigenetic Regulation in the Pacific Oyster
PAG Jan 2011: Epigenetic Regulation in the Pacific OysterPAG Jan 2011: Epigenetic Regulation in the Pacific Oyster
PAG Jan 2011: Epigenetic Regulation in the Pacific Oyster
 
DNA Repair
DNA RepairDNA Repair
DNA Repair
 
ResearchPoster_USFHealthFair
ResearchPoster_USFHealthFairResearchPoster_USFHealthFair
ResearchPoster_USFHealthFair
 
Medicinal application of organometallic compounds
Medicinal application of organometallic compoundsMedicinal application of organometallic compounds
Medicinal application of organometallic compounds
 

Viewers also liked

FINAL presentation
FINAL presentationFINAL presentation
FINAL presentationColm Farrell
 
J. Biol. Chem.-2002-Gaidarova-38737-45
J. Biol. Chem.-2002-Gaidarova-38737-45J. Biol. Chem.-2002-Gaidarova-38737-45
J. Biol. Chem.-2002-Gaidarova-38737-45Svetlana Gaidarova
 
Spring Research 2016-MP
Spring Research 2016-MPSpring Research 2016-MP
Spring Research 2016-MPMark Philipson
 
Organometallic chemistry
Organometallic chemistryOrganometallic chemistry
Organometallic chemistryFari Ba
 
Chemistry of DNA
Chemistry of DNAChemistry of DNA
Chemistry of DNAAshok Katta
 
The Epic Collision of Marketing & Technology
The Epic Collision of Marketing & TechnologyThe Epic Collision of Marketing & Technology
The Epic Collision of Marketing & Technologyion interactive
 

Viewers also liked (10)

SACNAS EDC Poster
SACNAS EDC PosterSACNAS EDC Poster
SACNAS EDC Poster
 
FINAL presentation
FINAL presentationFINAL presentation
FINAL presentation
 
J. Biol. Chem.-2002-Gaidarova-38737-45
J. Biol. Chem.-2002-Gaidarova-38737-45J. Biol. Chem.-2002-Gaidarova-38737-45
J. Biol. Chem.-2002-Gaidarova-38737-45
 
Spring Research 2016-MP
Spring Research 2016-MPSpring Research 2016-MP
Spring Research 2016-MP
 
Drug dna interaction
Drug dna interactionDrug dna interaction
Drug dna interaction
 
Organometallic chemistry
Organometallic chemistryOrganometallic chemistry
Organometallic chemistry
 
Chemistry of DNA
Chemistry of DNAChemistry of DNA
Chemistry of DNA
 
DNA Replication
 DNA Replication DNA Replication
DNA Replication
 
The Epic Collision of Marketing & Technology
The Epic Collision of Marketing & TechnologyThe Epic Collision of Marketing & Technology
The Epic Collision of Marketing & Technology
 
Slideshare ppt
Slideshare pptSlideshare ppt
Slideshare ppt
 

Similar to SERMACSposterDr.V

MIT Amgen Scholar Presentation
MIT Amgen Scholar PresentationMIT Amgen Scholar Presentation
MIT Amgen Scholar PresentationBrandon Clark
 
Lynch CERCA Poster S16 [4196]
Lynch CERCA Poster S16 [4196]Lynch CERCA Poster S16 [4196]
Lynch CERCA Poster S16 [4196]Andrew Lynch
 
S. prasanth kumar young scientist awarded presentation
S. prasanth kumar young scientist awarded presentationS. prasanth kumar young scientist awarded presentation
S. prasanth kumar young scientist awarded presentationPrasanthperceptron
 
Molecular mechanisms in crpc
Molecular mechanisms in crpcMolecular mechanisms in crpc
Molecular mechanisms in crpcAlok Gupta
 
Fundamentals Of Genetic Toxicology In The Pharmaceutical Industry Sept 2010
Fundamentals Of Genetic Toxicology In The Pharmaceutical Industry Sept 2010Fundamentals Of Genetic Toxicology In The Pharmaceutical Industry Sept 2010
Fundamentals Of Genetic Toxicology In The Pharmaceutical Industry Sept 2010TigerTox
 
Oral presentation at Protein Folding Consortium Workshop in St Louis
Oral presentation at Protein Folding Consortium Workshop in St LouisOral presentation at Protein Folding Consortium Workshop in St Louis
Oral presentation at Protein Folding Consortium Workshop in St LouisTemple University
 
cancer nice paper.pdf
cancer nice paper.pdfcancer nice paper.pdf
cancer nice paper.pdfasthabisht789
 
Aacr2009 methylprofiler
Aacr2009 methylprofilerAacr2009 methylprofiler
Aacr2009 methylprofilerElsa von Licy
 
Stress-Induced Tumorigenesis
Stress-Induced TumorigenesisStress-Induced Tumorigenesis
Stress-Induced TumorigenesisMax Goldman
 
Beyer MDM2 Publication 2016.PDF
Beyer MDM2 Publication 2016.PDFBeyer MDM2 Publication 2016.PDF
Beyer MDM2 Publication 2016.PDFGeorge Beyer
 
Peptidimimetics in the Treatment of Cancer
Peptidimimetics in the Treatment of CancerPeptidimimetics in the Treatment of Cancer
Peptidimimetics in the Treatment of CancerYogesh Morjaria
 

Similar to SERMACSposterDr.V (20)

MI-4
MI-4MI-4
MI-4
 
SBR Final Presentaion
SBR Final PresentaionSBR Final Presentaion
SBR Final Presentaion
 
MIT Amgen Scholar Presentation
MIT Amgen Scholar PresentationMIT Amgen Scholar Presentation
MIT Amgen Scholar Presentation
 
Lynch CERCA Poster S16 [4196]
Lynch CERCA Poster S16 [4196]Lynch CERCA Poster S16 [4196]
Lynch CERCA Poster S16 [4196]
 
defense 2.0
defense 2.0defense 2.0
defense 2.0
 
S. prasanth kumar young scientist awarded presentation
S. prasanth kumar young scientist awarded presentationS. prasanth kumar young scientist awarded presentation
S. prasanth kumar young scientist awarded presentation
 
publication 1
publication 1publication 1
publication 1
 
Genetic instability
Genetic instabilityGenetic instability
Genetic instability
 
Molecular mechanisms in crpc
Molecular mechanisms in crpcMolecular mechanisms in crpc
Molecular mechanisms in crpc
 
Fundamentals Of Genetic Toxicology In The Pharmaceutical Industry Sept 2010
Fundamentals Of Genetic Toxicology In The Pharmaceutical Industry Sept 2010Fundamentals Of Genetic Toxicology In The Pharmaceutical Industry Sept 2010
Fundamentals Of Genetic Toxicology In The Pharmaceutical Industry Sept 2010
 
Mutation and DNA repair
Mutation and DNA repairMutation and DNA repair
Mutation and DNA repair
 
Oral presentation at Protein Folding Consortium Workshop in St Louis
Oral presentation at Protein Folding Consortium Workshop in St LouisOral presentation at Protein Folding Consortium Workshop in St Louis
Oral presentation at Protein Folding Consortium Workshop in St Louis
 
cancer nice paper.pdf
cancer nice paper.pdfcancer nice paper.pdf
cancer nice paper.pdf
 
Aacr2009 methylprofiler
Aacr2009 methylprofilerAacr2009 methylprofiler
Aacr2009 methylprofiler
 
Stress-Induced Tumorigenesis
Stress-Induced TumorigenesisStress-Induced Tumorigenesis
Stress-Induced Tumorigenesis
 
IACR 2016 poster
IACR 2016 posterIACR 2016 poster
IACR 2016 poster
 
Beyer MDM2 Publication 2016.PDF
Beyer MDM2 Publication 2016.PDFBeyer MDM2 Publication 2016.PDF
Beyer MDM2 Publication 2016.PDF
 
Peptidimimetics in the Treatment of Cancer
Peptidimimetics in the Treatment of CancerPeptidimimetics in the Treatment of Cancer
Peptidimimetics in the Treatment of Cancer
 
Dna methylation
Dna methylationDna methylation
Dna methylation
 
Dna methylation
Dna methylationDna methylation
Dna methylation
 

SERMACSposterDr.V

  • 1. DNA binding, DNA Methylation and Cell Toxicity of Estradiol Conjugated DNA Methylating Compounds Estrogen Receptor Binding :FRET Assay Cell Toxicity DNA Methylation Design of Molecules Acknowledgments Matthew Powella, Sean Millera, Rigel Kishtona, Charles Kellya, Kelly Mastroa, Astrid Linaresb, Manoj Chelvanambib, Vinayak K. Gorec, Giridhar R. Akkarajub Sridhar Varadarajana,*aDepartment of Chemistry and Biochemistry, University of North Carolina Wilmington, Wilmington, NC, bDepartment of Biology, Texas Christian University, Fort Worth, TX, cQuality Chemical Laboratories, Wilmington, NC. Abstract Estradiol conjugated compounds that can target estrogen receptor positive cells and produce lethal N3-methyladenine adducts in these cells have been synthesized and investigated1. Prior studies with these DNA methylating compounds had shown that the ability of these molecules to produce N3-methyladenine adducts was crucially dependent on the composition of the linker unit connecting the DNA methylating moiety to the estradiol unit. The DNA binding properties of this class of molecules was investigated using stable non-methylating analogs, and the variation in the DNA binding ability of the compounds was compared to the corresponding DNA methylating ability. Cell toxicity studies were conducted using MCF-7 breast cancer cells in order to determine any correlation between toxicity and DNA methylation and estrogen receptor binding. The results of these studies are presented. References 0 20 40 60 80 100 120 140 0 20 40 60 80 100 120 %Control(CellSurvival) Concentration (uM) Cell Survival Melex 1a 2a 3a Linear (Melex) Linear (1a) Linear (2a) Linear (3a) 0 20 40 60 80 100 120 140 0 20 40 60 80 100 120 %Control(CellSurvival) Concentration (uM) Cell Survival - Control Control 1b 2b 3b Linear (Control) Linear (1b) Linear (2b) Linear (3b) Compound IC50 (nM) Relative Binding Affinity Estradiol 0.58 100% 1b 0.99 58% 2b 1.48 39% 3b 1.11 52% Synthesis of Molecules3 • Toxicity of compounds was determined in MCF-7 breast cancer cells that overexpress estrogen receptor-α. • All methyl-sulfonates were toxic to MCF- 7 cells, with compound 2a being the most toxic (EC50 ≈ 40 μM ), followed by 3a, and then 1a. • All sulfone analogues were not toxic to MCF-7 cells. • 3Me-A is the predominant adduct formed by all three compounds • Compound 2a produces significantly higher levels of 3-MeA relative to the other compounds. Possible explanation for the variation in DNA binding of compounds. 1. Franza, Gilberto, and Barry Gold. "The Biological Effects of N3- methyladenine." Journal of Cellular Biochemistry 19.2 (2004): 250-257. Web. Aug. & Sept. 2013. 2. Charles Kelly 3. Kishton, Rigel, Sean E. Miller, Heather Perry, Tera Lynch, Mayur Patel, Vinayak K. Gore, and Giridhar R. Akkaraju. "DNA Site-specific N3-adenine Methylation Targeted to Estrogen Receptor-positive Cells." Biorganic and Medicinal Chemistry 195093-5102. This project was funded in part by: the NC Biotechnology Center Research Grant (#CC6425), the Research Corporation (#2008BRG1214), the GlaxoSmithKline Summer Undergraduate Research Scholarship, and the UNCW CSURF Research Supplies award, UNCW CSURF Undergraduate Fellowships, and the UNCW Charles L. Cahill Award. We also thank Dr. Suzanne Wardell and Dr. Donald McDeonnell for help with gene transcription studies. Compound 2 Compound 1 Table 1 DNA adduct levels obtained upon reaction of compounds with calf thymus DNAa Comp- ound conc µM netrop µM adduct level µmol adduct/mol DNA 3-MeA 7-MeG 1 25 1615 ± 45 194 ± 35 50 1764 ± 17 280 ± 36 100 1922 ± 35 404 ± 109 100 100 180 ± 10 482 ± 57 2 25 6523 ± 363 93 ± 31 50 11131 ± 30 253 ± 10 100 14449 ± 161 495 ± 35 100 100 769 ± 42 409 ± 3 3 25 699 ± 19 147 ± 20 50 922 ± 31 204 ± 25 100 1206 ± 23 318 ± 15 100 100 173 ± 16 420 ± 73 Me-lex 25 4599 ± 385 185 ± 59 50 8234 ± 542 399 ± 108 100 14280 ± 1250 774 ± 73 100 100 657 ± 12 714 ± 67 MMS 5000 1799 ± 39 18067 ± 76 5000 100 1239 ± 88 18935 ± 502 a DNA (1 mM) was reacted with methylating compounds, in the presence or absence of netropsin, for 24 h at RT in 10 mM sodium cacodylate buffer (pH 7.0) containing 10% DMSO. 0 2000 4000 6000 8000 10000 12000 14000 16000 1 2 3 Me-lex MMS Adduct levels (μmol adduct/mol DNA) 3-MeA 7-MeG DNA Binding: Fluorescent Intercalator Displacement Assay Estrogen Receptor Gene Transcription A. Duplex DNA B. Ethidium bromide intercalated DNA exhibits fluorescence enhancement. C. EtBris displaced by ligand and fluorescence diminishes. 800000 1000000 1200000 1400000 1600000 1800000 2000000 1 2 3 4 5 6 7 FluorescenceIntensity molar eq. compound DNA Binding Assay 4.72 eq. 4.43 eq. 2.54 eq. 1b 2b 3b • Compounds act as SERMS. • Stereoview of compound 3a bound in the minor groove of DNA2